Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples